Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single-Use Equipment), Process (Cell Processing, Preservation), Cell type (T-Cells, Stem cells), End User (Biopharma, CROs, CMOs), Region - Global Forecast to 2028
The global cell therapy technologies market size is projected to reach USD 7.8 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 13.3 % during the forecast period. Factors such as increasing government investments in cell-based research, rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, increasing GMP certification for cell therapy production facilities are likely to have positive impact on the market growth.
“The process segment held the dominant share in the cell therapy technologies market”
Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022. Advancement in cell processing techniques is likely to have positive impact on the growth of the market.
“Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022.”
Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOS, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.
“Asia Pacific region is likely to grow at a faster pace.”
The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process,cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The process segment held the dominant share in the cell therapy technologies market”
Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022. Advancement in cell processing techniques is likely to have positive impact on the growth of the market.
“Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022.”
Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOS, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.
“Asia Pacific region is likely to grow at a faster pace.”
The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70%, and Demand Side - 30%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
- Thermo Fisher Scientific, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Lonza Group (Switzerland)
- Sartorius AG(Germany)
- Terumo Bct, Inc Corporation (Japan) (Terumo BCT is part of Terumo Corporation)
- Becton, Dickinson & Company (US)
- Fresenius Se & co. KGaA (Germany)
- Avantor Inc (US)
- Bio-Techne (US)
- Corning Incorporated (US)
- Fujifilm Irvine Scientific (Japan)
- Maxcyte Inc. (US)
- Werum Software & Systems AG (Part of Korber AG) (Germany)
- Roosterbio Inc. (US)
- Sirion Biotech Gmbh (Germany)
- Trakcel (UK)
- L 7 Informatics Inc. (US)
- Miltenyi Biotech (Germany)
- Steamcell Technologies Inc. (Canada)
- GPI Iberia (Formerly Hemasoft) (Spain)
- CodexThemes (France)
- Organabio LLC. (US)
- Ixcells Biotechnologies (US)
- Wilson Wolf 2019 Manufacturing Corporation (US)
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process,cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing government investments in cell-based research, Rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, Increasing GMP certification for cell therapy production facilities), restraints ( High cost of cell-based research and low success rate), opportunities (Emergence of iPSC as alternatives to ESCs, Increased focus on personalized medicine, Increasing public-private partnerships for development of cell therapies, Emerging Asian markets), and challenges (Survival for small players and new entrants)are influencing the growth of cell therapy technologies market.
- Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the Cell therapy technologies market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the cell therapy technologies market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023–2028
FIGURE CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES
4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028
FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION)
FIGURE 1 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing government investments in cell-based research
TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2022 (USD MILLION)
5.2.1.2 Rising incidence of chronic and infectious diseases
5.2.1.3 Large number of oncology-related cell therapy clinical trials
FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021–2022
5.2.1.4 Increasing GMP certifications for cell therapy production facilities
TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
5.2.2 RESTRAINTS
5.2.2.1 High cost of cell-based research and low success rate
TABLE 6 COST OF CELL THERAPY EQUIPMENT
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of iPSCs as alternatives to ESCs
5.2.3.2 Increased focus on personalized medicine
5.2.3.3 Increasing partnerships for development of cell therapies
5.2.3.4 Emerging Asian markets
5.2.4 CHALLENGES
5.2.4.1 Survival of small players and new entrants
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
5.4 INDICATIVE PRICING MODEL ANALYSIS
TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET
FIGURE 26 ECOSYSTEM ANALYSIS
TABLE 8 SUPPLY CHAIN ECOSYSTEM
5. KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES
5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 1 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 DEGREE OF COMPETITION
5.12 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013–JULY 2023
TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
FIGURE 2 KEY BUYING CRITERIA FOR END USERS
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 MEDIA, SERA, AND REAGENTS
6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 CELL ENGINEERING PRODUCTS
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 2 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 CELL CULTURE VESSELS
6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS
TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 CELL THERAPY EQUIPMENT
TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021–2028 (USD MILLION)
TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 3 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.1 CELL PROCESSING EQUIPMENT
6.5.1.1 Cell processing equipment to dominate market
TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.2 SINGLE-USE EQUIPMENT
6.5.2.1 Benefits of single-use equipment to ensure end-user demand
TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.3 OTHER EQUIPMENT
TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 4 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 SYSTEMS & SOFTWARE
6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND
TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 OTHER PRODUCTS
TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 5 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS
7.1 INTRODUCTION
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
7.2 CELL PROCESSING
7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028
TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 PROCESS MONITORING & QUALITY CONTROL
7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION
TABLE 6 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE
8.1 INTRODUCTION
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
8.2 T CELLS
8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 STEM CELLS
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 7 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 OTHER CELLS
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
CELL THERAPY TECHNOLOGIES MARKET, BY END USER
9.1 INTRODUCTION
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET
TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 8 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 CROS & CMOS
9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021–2028 (USD MILLION)
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 RESEARCH INSTITUTES & CELL BANKS
9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021–2028 (USD MILLION)
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION
10.1 INTRODUCTION
TABLE 9 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Increasing R&D activities to support market growth
TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 10 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 11 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Germany to hold largest share of European market
TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Favorable funding and investment scenario to drive market
TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 12 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Availability of government and private support to drive market
TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth
TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 13 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Increasing funding from private and public organizations to aid market growth
TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 14 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
10.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Increasing cell therapy-based trials to support market growth
TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 15 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Rising geriatric population and growing disease prevalence to drive market
TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022
TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Favorable government regulations to support market growth
TABLE 16 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET
10.5.2 LATIN AMERICA: RECESSION IMPACT
TABLE 17 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE SHARE ANALYSIS
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
11.4 MARKET SHARE ANALYSIS
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
TABLE 18 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX, 2022
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES)
TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
11.7.1 PROGRESSIVE COMPANIES
11.7.2 STARTING BLOCKS
11.7.3 RESPONSIVE COMPANIES
11.7.4 DYNAMIC COMPANIES
FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
11. COMPETITIVE SCENARIO AND TRENDS
11.9.1 PRODUCT LAUNCHES
TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
11.9.2 DEALS
TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020–APRIL 2023
11.9.3 OTHER DEVELOPMENTS
TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
12 COMPANY PROFILES
12.1 KEY MARKET PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
12.1.2 MERCK KGAA
TABLE 19 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.3 DANAHER CORPORATION
TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 3 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.4 LONZA GROUP
TABLE 201 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022)
12.1.5 SARTORIUS AG
TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022)
12.1.6 TERUMO BCT, INC.
TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW
FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
12.1.7 BECTON DICKINSON AND COMPANY
TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.8 FRESENIUS SE & CO. KGAA
TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022)
12.1. AVANTOR, INC.
TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW
FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022)
12.1.10 BIO-TECHNE
TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022)
12.1.11 CORNING INCORPORATED
TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
12.1.12 FUJIFILM IRVINE SCIENTIFIC
TABLE 20 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022)
12.1.13 MAXCYTE, INC.
TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW
FIGURE 4 MAXCYTE, INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 WERUM IT SOLUTIONS
12.2.2 ROOSTERBIO, INC.
12.2.3 SIRION BIOTECH
12.2.4 TRAKCEL
12.2.5 L7 INFORMATICS, INC.
12.2.6 MILTENYI BIOTEC B.V. & CO. KG
12.2.7 STEMCELL TECHNOLOGIES
12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
12.2. MAK-SYSTEM
12.2.10 ORGANABIO
12.2.11 IXCELLS BIOTECHNOLOGIES
12.2.12 WILSON WOLF
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023–2028
FIGURE CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES
4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028
FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION)
FIGURE 1 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing government investments in cell-based research
TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2022 (USD MILLION)
5.2.1.2 Rising incidence of chronic and infectious diseases
5.2.1.3 Large number of oncology-related cell therapy clinical trials
FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021–2022
5.2.1.4 Increasing GMP certifications for cell therapy production facilities
TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
5.2.2 RESTRAINTS
5.2.2.1 High cost of cell-based research and low success rate
TABLE 6 COST OF CELL THERAPY EQUIPMENT
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of iPSCs as alternatives to ESCs
5.2.3.2 Increased focus on personalized medicine
5.2.3.3 Increasing partnerships for development of cell therapies
5.2.3.4 Emerging Asian markets
5.2.4 CHALLENGES
5.2.4.1 Survival of small players and new entrants
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
5.4 INDICATIVE PRICING MODEL ANALYSIS
TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET
FIGURE 26 ECOSYSTEM ANALYSIS
TABLE 8 SUPPLY CHAIN ECOSYSTEM
5. KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES
5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 1 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 DEGREE OF COMPETITION
5.12 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013–JULY 2023
TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
FIGURE 2 KEY BUYING CRITERIA FOR END USERS
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 MEDIA, SERA, AND REAGENTS
6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 CELL ENGINEERING PRODUCTS
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 2 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 CELL CULTURE VESSELS
6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS
TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 CELL THERAPY EQUIPMENT
TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021–2028 (USD MILLION)
TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 3 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.1 CELL PROCESSING EQUIPMENT
6.5.1.1 Cell processing equipment to dominate market
TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.2 SINGLE-USE EQUIPMENT
6.5.2.1 Benefits of single-use equipment to ensure end-user demand
TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.3 OTHER EQUIPMENT
TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 4 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 SYSTEMS & SOFTWARE
6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND
TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 OTHER PRODUCTS
TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 5 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS
7.1 INTRODUCTION
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
7.2 CELL PROCESSING
7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028
TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 PROCESS MONITORING & QUALITY CONTROL
7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION
TABLE 6 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE
8.1 INTRODUCTION
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
8.2 T CELLS
8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 STEM CELLS
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 7 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 OTHER CELLS
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
CELL THERAPY TECHNOLOGIES MARKET, BY END USER
9.1 INTRODUCTION
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET
TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 8 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 CROS & CMOS
9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021–2028 (USD MILLION)
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 RESEARCH INSTITUTES & CELL BANKS
9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021–2028 (USD MILLION)
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION
10.1 INTRODUCTION
TABLE 9 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Increasing R&D activities to support market growth
TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 10 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 11 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Germany to hold largest share of European market
TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Favorable funding and investment scenario to drive market
TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 12 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Availability of government and private support to drive market
TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth
TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 13 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Increasing funding from private and public organizations to aid market growth
TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 14 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
10.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Increasing cell therapy-based trials to support market growth
TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 15 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Rising geriatric population and growing disease prevalence to drive market
TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022
TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Favorable government regulations to support market growth
TABLE 16 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET
10.5.2 LATIN AMERICA: RECESSION IMPACT
TABLE 17 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE SHARE ANALYSIS
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
11.4 MARKET SHARE ANALYSIS
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
TABLE 18 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX, 2022
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES)
TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
11.7.1 PROGRESSIVE COMPANIES
11.7.2 STARTING BLOCKS
11.7.3 RESPONSIVE COMPANIES
11.7.4 DYNAMIC COMPANIES
FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
11. COMPETITIVE SCENARIO AND TRENDS
11.9.1 PRODUCT LAUNCHES
TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
11.9.2 DEALS
TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020–APRIL 2023
11.9.3 OTHER DEVELOPMENTS
TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
12 COMPANY PROFILES
12.1 KEY MARKET PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
12.1.2 MERCK KGAA
TABLE 19 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.3 DANAHER CORPORATION
TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 3 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.4 LONZA GROUP
TABLE 201 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022)
12.1.5 SARTORIUS AG
TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022)
12.1.6 TERUMO BCT, INC.
TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW
FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
12.1.7 BECTON DICKINSON AND COMPANY
TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.8 FRESENIUS SE & CO. KGAA
TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022)
12.1. AVANTOR, INC.
TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW
FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022)
12.1.10 BIO-TECHNE
TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022)
12.1.11 CORNING INCORPORATED
TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
12.1.12 FUJIFILM IRVINE SCIENTIFIC
TABLE 20 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022)
12.1.13 MAXCYTE, INC.
TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW
FIGURE 4 MAXCYTE, INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 WERUM IT SOLUTIONS
12.2.2 ROOSTERBIO, INC.
12.2.3 SIRION BIOTECH
12.2.4 TRAKCEL
12.2.5 L7 INFORMATICS, INC.
12.2.6 MILTENYI BIOTEC B.V. & CO. KG
12.2.7 STEMCELL TECHNOLOGIES
12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
12.2. MAK-SYSTEM
12.2.10 ORGANABIO
12.2.11 IXCELLS BIOTECHNOLOGIES
12.2.12 WILSON WOLF
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
